ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Genenta Science SPA

Genenta Science SPA (GNTA)

3.85
0.55
(16.67%)
At close: September 19 4:00PM
3.85
0.00
( 0.00% )
After Hours: 5:38PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
3.85
Bid
3.36
Ask
4.94
Volume
3,307
3.30 Day's Range 3.85
0.00 52 Week Range 0.00
Market Cap
Previous Close
3.30
Open
3.30
Last Trade
5
@
3.82
Last Trade Time
17:48:00
Financial Volume
$ 11,048
VWAP
3.3408
Average Volume (3m)
-
Shares Outstanding
18,216,958
Dividend Yield
-
PE Ratio
-6.60
Earnings Per Share (EPS)
-0.58
Revenue
465k
Net Profit
-10.62M

About Genenta Science SPA

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's product under development includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affec... Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's product under development includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy. Show more

Sector
Health Practitioners, Nec
Industry
Health Practitioners, Nec
Website
Headquarters
Milan, Lombardy, Ita
Founded
-
Genenta Science SPA is listed in the Health Practitioners sector of the NASDAQ with ticker GNTA. The last closing price for Genenta Science was $3.30. Over the last year, Genenta Science shares have traded in a share price range of $ 0.00 to $ 0.00.

Genenta Science currently has 18,216,958 shares outstanding. The market capitalization of Genenta Science is $60.12 million. Genenta Science has a price to earnings ratio (PE ratio) of -6.60.

GNTA Latest News

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the...

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power...

Genenta to Present at Upcoming Scientific and Investor Conferences

MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power...

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science...

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of...

Genenta to Provide Update on Lead Product Temferon™

MILAN, Italy and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini, Ph.D., M.D., co-founder and Executive Scientific Board Chairman of Genenta Science S.p.A. (NASDAQ: GNTA), a...

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025Net exchange rate gain of €2.3 millionTax credit of €6.4 million MILAN...

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

MILAN, Italy, July 25, 2022 (GLOBE NEWSWIRE) -- Bowling Green Bull (BGB) is an initiative to connect Italian companies, entrepreneurs and top managers aiming for international growth and...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LFLYLeafly Holdings Inc
$ 3.76
(110.06%)
4.54M
AENTAlliance Entertainment Holding Corporation
$ 2.84
(39.22%)
121.18k
AGBAAGBA Group Holding Ltd
$ 2.75
(30.33%)
1.15M
TNONTenon Medical Inc
$ 6.40
(27.24%)
2.52M
AEMDAethlon Medical Inc
$ 0.4937
(26.59%)
8.3M
EJHE Home Household Service Holdings Ltd
$ 0.0752
(-22.95%)
8.47M
KOPNKopin Corporation
$ 0.819
(-15.05%)
188.93k
NCINeo Concept International Group Holdings Ltd
$ 0.725
(-13.69%)
1.52M
VEROVenus Concept Inc
$ 0.7602
(-11.60%)
436.33k
MYNAMynaric AG
$ 1.1602
(-9.36%)
108.05k
EJHE Home Household Service Holdings Ltd
$ 0.0752
(-22.95%)
8.47M
AEMDAethlon Medical Inc
$ 0.4937
(26.59%)
8.3M
HSTHost Hotels and Resorts Inc
$ 18.53
(0.00%)
6.45M
LFLYLeafly Holdings Inc
$ 3.76
(110.06%)
4.54M
SQQQProShares UltraPro Short QQQ
$ 7.78
(0.26%)
4.25M

GNTA Discussion

View Posts
Awl416 Awl416 2 months ago
What leaked
👍️0
Monksdream Monksdream 5 months ago
GNTA under $3
👍️0
Luckypennyman Luckypennyman 2 years ago
FDA’s decision to grant Orphan Drug Designation to Temferon









glta
👍️0
makinezmoney makinezmoney 2 years ago
$GNTA: Just got a $15 PriceTarget upgrade.

From here $5, looks like its gonna be a nice ride up


GO $GNTA
👍️0
conix conix 3 years ago
Maxim starts Genenta Science at buy; PT $21

Stephen Kilmer

January 13, 2022

Maxim Group launched coverage of Genenta Science S.p.A (NASDAQ:GNTA) with a “buy” rating and $21 price target. The stock closed at $9.94 on Jan. 12.

Genenta is developing cancer therapeutics using an autologous ex-vivo, lentiviral-based gene therapy strategy.

The company initially is targeting unmethylated-MGMT glioblastoma multiforme (GBM) patients with its lead gene therapy, Temferon, which is currently being evaluated in a Phase 1/2 dose-escalation study. Data from the latter two cohorts are expected around the end of 2022.

“Tumor agnostic gene therapy, Temferon, can potentially be applied broadly to multiple cancer types because it is not tumor dependent,” writes analyst Naureen Quibria, Ph.D.

She said lentiviral-based gene therapy is a validated approach, with treatment approvals seen in Kymriah for acute lymphoblastic leukemia and diffuse large B-cell lymphoma, Zynteglo for ß-thalassemia, and Libmeldy for metachromatic leukodystrophy.

Genenta’s Temferon, has also demonstrated initial signals of efficacy in its Phase 1/2 clinical study in GBM, as well as robust activity in multiple tumor models in preclinical studies.

“Though the program is somewhat early, we believe the broad utility of the platform and potential durability of the approach support a ‘buy’ rating and our $21 price target,” Dr. Quibria said.
👍️0
asser_al7ob asser_al7ob 3 years ago
is this genta that we have before, it is coming back after years
👍️0
Phosphene Phosphene 3 years ago
Clinical-stage biotechnology company pioneering
the development of lentivirus-based first-in-class
gene and cell therapies in cancer.

Genenta uses gene-based cytokine delivery
to activate the immune system within the tumor,
providing a controlled, targeted and enduring anti-tumor response.

https://www.genenta.com/

TEM-GBM_001

👍️0

Your Recent History

Delayed Upgrade Clock